Our study does not support the reduced expression of IDO1 and ARG1 in PBMCs from Argentinian patients with clinically definite, relapsing–remitting MS.14 To explain differences in study outcomes, 62% of the Argentinian cohort were taking IFN‐β1α or glatiramer acetate. This evidence concerns the gene IDO1 and myeloid sarcoma.